Ireland
--:--IST
Latest
Active, not recruiting Not applicable

PROSpect: Prone and Oscillation Pediatric Clinical Trial

NCT03896763 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2019-05-01
Last updated
2026-05-05

Condition(s) studied

Acute Respiratory Distress Syndrome in Children

Investigational drug(s) / intervention(s)

Either supine or prone positioning and either CMV or HFOV

Either supine or prone positioning and either CMV or HFOV: Supine positioning: Subjects randomized to supine positioning will remain supine. Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days. CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid. HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.

Study summary

Severe pediatric acute respiratory distress syndrome (PARDS) is a life-threatening and frequent problem experienced by thousands of children each year. Little evidence supports current supportive practices during their critical illness. The overall objective of this study is to identify the best positional and/or ventilation practice that leads to improved patient outcomes in these critically ill children. We hypothesize that children with high moderate-severe PARDS treated with either prone positioning or high-frequency oscillatory ventilation (HFOV) will demonstrate more days off the ventilator when compared to children treated with supine positioning or conventional mechanical ventilation (CMV).

Eligibility

Sex
ALL
Min age
2 Weeks
Max age
20 Years
Healthy volunteers
No
Inclusion criteria: Intubated and mechanically ventilated with high moderate-severe PARDS for \<48 hours per PALICC guidelines (chest imaging consistent with acute pulmonary parenchymal disease and OI ≥12 or OSI ≥10). We require two blood gases meeting moderate-severe PARDS criteria (separated by at least 4 ± 2 hours during which time the clinical team is actively working to recruit lung volume and optimize the patient's hemodynamic status per PALICC guidelines; specifically, incremental and decremental PEEP changes to optimize lung volume). A second blood gas is not required for OI ≥16. Exclusion criteria: * Perinatal related lung disease * Unrepaired congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis * Respiratory failure explained by cardiac failure or fluid overload * Cyanotic heart disease * Cardiomyopathy * Unilateral lung disease * Primary pulmonary hypertension * Intubated for status asthmaticus * Obstructive airway disease (e.g., Severe airways disease without parenchymal involvement or disease characterized by hypercapnia with FiO2 \<0.30 and/or evidence of increased resistance visible on the flow - time scalar and/or presence of intrinsic PEEP) * Active air leak * Bronchiolitis obliterans * Post hematopoietic stem cell transplant; specifically, patients receiving continuous supplemental oxygen for three or more days prior to intubation; receiving noninvasive ventilation for more than 24 hours prior to intubation; receiving more than one vasoactive medication at time of meeting inclusion criteria; spending more than four days in the PICU prior to intubation; supported on or with immediate plans for renal replacement therapies; with two or more allogeneic transplants; who relapsed after the transplant; or with diffuse alveolar hemorrhage * Post lung transplant * Home ventilator dependent with baseline Oxygen Saturation Index (OSI) \>6 * Neuromuscular respiratory failure * Critical airway (e.g., post laryngotracheal surgery or new tracheostomy) or anatomical obstruction of the lower airway (e.g., mediastinal mass) * Facial surgery or trauma in previous 2 weeks * Head trauma (managed with hyperventilation) * Intracranial bleeding * Unstable spine, femur or pelvic fractures * Open abdomen * Currently receiving more than 6 consecutive hours of either prone positioning or HFOV * Supported on ECMO during the current admission * Family/medical team not providing full support (patient treatment considered futile) * Previously enrolled in current study * Enrolled in any other interventional clinical trial not approved for co-enrollment * Known pregnancy

Primary outcome measure(s)

  • Ventilator-free Days (VFD) — 28 days
    Our primary research hypothesis is that children with severe PARDS randomized to either prone positioning or HFOV will demonstrate more ventilator-free days. We hypothesize that a superior treatment would improve VFD by at least 2 days, a clinically meaningful difference. VFD is the number of days within 28 days that a patient is alive and free of mechanical ventilation. Improvement in VFD will be considered within the context of patient safety; specifically, patients must also exhibit a similar safety profile.

Trial sites (49)

FacilityCityRegionStatus
Children's of Alabama Birmingham Alabama
Banner Health Phoenix Arizona
Arkansas Children's Hospital Little Rock Arkansas
Children's Hospital Orange County Orange California
Stanford Children's Health Palo Alto California
Kapiolani Medical Center for Women and Children Honolulu Hawaii
Ann & Robert Lurie Children's Hospital of Chicago Chicago Illinois
Riley Hospital for Children at IU Health Indianapolis Indiana
University of Iowa Stead Family Chlldren's Hospital Iowa City Iowa
Norton Children's Hospital Louisville Kentucky
Bloomberg Children's Center, Johns Hopkins University Baltimore Maryland
CS Mott Children's Hospital Ann Arbor Michigan
Children's Hospital and Medical Center Omaha Nebraska
Cohen Children's Medical Center Queens New York
Duke Children's Hospital Durham North Carolina
UH Rainbow Babies & Children Cleveland Ohio
Children's Hospital at Oklahoma University Medical Center Oklahoma City Oklahoma
Penn State Children's Hospital Hershey Pennsylvania
Children's Hospital of Philadelphia Philadelphia Pennsylvania
Medical University of South Carolina Charleston South Carolina
LeBonheur Children's Hospital Memphis Tennessee
Medical City Dallas Dallas Texas
Children's Health Dallas Dallas Texas
Texas Children's Hospital Houston Texas
Children's Hospital of San Antonio San Antonio Texas
Inova Fairfax Medical Campus Falls Church Virginia
American Family Children's Hospital, University of Wisconsin Madison Wisconsin
Children's Hospital of Wisconsin Milwaukee Wisconsin
Hospital de Pediatría J. P. Garrahan. SAMIC Buenos Aires Buenos Aires F.D.
Perth Children's Hospital Perth Western Australia
Children's Hospital at Westmead Sydney Australia
Sabara Hospital Infantil São Paulo Brazil
Hospital SEPACO São Paulo Brazil
Centre Hospitalier Universitaire Sainte Justine Montreal Quebec
Münster University Hospital Münster Germany
Rainbow Children's Hospital Hyderabad India
Hadassah Medical Center Jerusalem Israel
Meyer Children's Hospital Florence Italy
Bambino Gesu Children's Hospital (Area Rossa Unit) Rome Italy
Instituto Giannina Gasilini Genova Italy

+ 9 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03896763 on ClinicalTrials.gov ↗ ← All trials in Germany